NVO vs RYTM: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. NVO and RYTM share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined NVO and RYTM exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Novo Nordisk (NVO) is a Danish pharmaceutical company and a global leader in diabetes and obesity care. Its franchise centers on GLP-1 receptor agonists, most notably semaglutide, sold as Ozempic and Rybelsus for type 2 diabetes and as Wegovy for chronic weight management. Novo Nordisk also holds a long-standing leadership position in insulin and broader diabetes therapies, and maintains smaller franchises in rare blood and endocrine disorders. The company is headquartered in Bagsvaerd, Denmark, and is controlled by the Novo Nordisk Foundation through a dual-share structure. US investors typically access it through the NVO American Depositary Receipt listed on the New York Stock Exchange, which represents the Danish B shares. The explosive demand for GLP-1 drugs for both diabetes and weight loss has made Novo Nordisk one of Europe's most valuable companies, while also straining its manufacturing capacity for injectable medicines.

Full NVO guide

Rhythm Pharmaceuticals is a Boston-based biopharmaceutical company focused on rare diseases of obesity caused by defects in the melanocortin-4 receptor (MC4R) pathway, the brain circuit that regulates hunger and energy balance. Its lead and only marketed product, IMCIVREE (setmelanotide), is an MC4R agonist first approved for certain rare genetic obesity disorders and Bardet-Biedl syndrome, and in March 2026 the FDA approved it for acquired hypothalamic obesity (weight gain caused by damage to the hypothalamus, often after brain tumors or their treatment). The company is also advancing bivamelagon, a next-generation oral MC4R agonist, and other early programs aimed at broadening its franchise across rare and anatomically driven forms of obesity.

Full RYTM guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• NVO drivers: GLP-1 obesity and diabetes demand; Pipeline and next-generation candidates.
• RYTM drivers: Acquired hypothalamic obesity launch; Existing genetic obesity and BBS base.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Novo Nordisk is heavily concentrated in a single drug class, so any clinical setback, safety signal, or faster-than-expected competition from Eli Lilly's tirzepatide (Mounjaro, Zepbound) and newer entrants directly threatens the core franchise. For RYTM, rhythm remains dependent on a single marketed product, IMCIVREE, so any safety, reimbursement, or competitive setback would hit the whole company.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick NVO if you believe its drivers more; RYTM if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the NVO and RYTM guides.

NVO. Novo Nordisk has historically commanded a premium pharma multiple on the strength of GLP-1 growth and very high margins. The multiple is sensitive to GLP-1 market-share dynamics versus Eli Lilly, supply progress, and US pricing news; disappointing trial data or share loss can compress it quickly. All figures are approximate, are reported in Danish kroner and translated to dollars, and should be verified against the latest filings.

RYTM. As of July 2026 Rhythm trades at a market cap near $8 billion against roughly $220 million in trailing revenue, a rich multiple that reflects expectations for rapid growth from the acquired hypothalamic obesity launch. The company is not profitable, funding launch and pipeline spending from its cash balance, which management has said should support operations for at least the next 24 months. These are approximate figures referenced to the July 2026 date and will change as new results are reported.

Headline figures (approximate, early 2026): NVO shows revenue (ttm) ~$40 billion (approximate, verify; reported in Danish kroner), operating margin ~45% (approximate, verify), net margin ~35% (approximate, verify), glp-1 share of revenue Majority of sales from semaglutide products (approximate); RYTM shows revenue (ttm) ~$220M, q1 2026 net product revenue ~$60.1M, q1 2026 net loss ~$55.6M, market cap ~$7.8B.

NVO and RYTM are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined NVO and RYTM exposure against your real portfolio. It is not an investment adviser.